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MTHFR C677T Polymorphism as a Risk Factor for Vascular 
Calcification in Chronic Hemodialysis Patients 
Polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T is one of the 
suggested risk factors for atherosclerosis. However, few studies have reported on the 
relationship between MTHFR C677T polymorphism and vascular calcification (VC) in chronic 
hemodialysis patients. We investigated the relationship between the MTHFR C677T 
polymorphism and VC in 152 chronic hemodialysis patients. Patients with a TT genotype 
exhibited significantly higher VC scores than patients expressing CC and CT (P = 0.002). 
The prevalence of peripheral vascular disease increased with the incidence of MTHFR C677T 
mutations for all patients, and the incidence of cerebrovascular accidents also increased 
with the presence of mutations for young patients (≤ 60 yr) (P < 0.05). Patients with CT 
and TT genotypes had adjusted odds ratios for VC of 1.39 and 1.58, respectively (P < 0.05). 
In summary, these data suggest that the MTHFR C677T polymorphism affects the degree 
of VC in chronic hemodialysis patients.
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BRIEF COMMUNICATION
Nephrology
Vascular calcification (VC) is a common manifestation of end-
stage renal disease (ESRD) (1, 2). The presence of VC is associ-
ated with aortic stiffness and is predictive of subsequent cardio-
vascular disease (CVD) and increased mortality (2). The exact 
pathophysiology of VC in ESRD patients is unclear. Recent stud-
ies have reported that VC is an active process regulated by vari-
ous genes and proteins (2). The 5,10-methylenetetrahydrofolate 
reductase (MTHFR) C677T polymorphism is associated with 
decreasing enzyme activity and increasing homocysteine (Hcy) 
levels (3). Elevated plasma Hcy is one of the suggested risk fac-
tors for atherosclerosis due to endothelial dysfunction and oxi-
dative stress (4). There is evidence for an association between 
increased plasma Hcy and the MTHFR polymorphism with an 
increased risk for developing CVD (5, 6). However, few studies 
have reported on the relationship between the MTHFR C677T 
polymorphism and VC in patients on chronic hemodialysis. 
Therefore, the goal of this study was to evaluate the degree of 
VC (7) and analyze the association with the MTHFR C677T poly-
morphism.
  After obtaining approval from the Institutional Review Board 
of Bundang CHA General Hospital, we recruited 152 patients. 
Inclusion criteria were ages 20-90 yr and the diagnosis of ESRD 
in patients that received chronic hemodialysis treatments for 
more than 3 months. Patients with acute infectious diseases or 
unstable vital signs were excluded. All patients provided written 
informed consent. 
  VC was evaluated by examining plain radiography of the pel-
vis and hands (7). The total final scores ranged from 0 to 8. Arte-
rial stiffness was assessed using a commercially available device 
(VP-2000, Colin Corporation, Komaki, Japan) that measures the 
pulse wave velocity (PWV). Pulse wave forms were obtained from 
the carotid and femoral artery sites. 
  Genomic DNA was extracted from peripheral blood leuko-
cytes using Puregene DNA extraction kits (QIAGEN, Valencia, 
CA, USA) according to the manufacturer’s protocols. The MTHFR 
C677T genotypes were identified as previously described (8).
  A routine clinical workup of all patients within 1 month of en-
rollment included fasting blood samples before the mid-week 
dialysis. Hcy levels were measured by chemiluminescence im-
munoassay. The level of total intact parathyroid hormone (iPTH) 
was evaluated by electrochemiluminescence immunoassay. 
  Statistical comparison between the groups was performed 
using the independent samples t-test, ANOVA, and chi-square 
tests. Predictive factors for VC were examined using logistic re-
gression analysis. P values less than 0.05 were considered statis-
tically significant.
  In terms of patients’ genotypes, 28.9% had CC, 47.4% had CT, 
and 23.7% had TT (Table 1). The patients with the TT genotype 
had higher VC scores than patients with the CC or CT genotype 
(P = 0.002). The TT genotype tended to be associated with a high-
er PWV, pulse pressure (PP), and prevalence of CVD; however, 
the differences were not statistically significant. Only the preva-Lee S-Y, et al.  •  The MTHFR Gene and Vascular Calcifications
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lence of peripheral vascular disease (PVD) was significantly in-
creased in patients with a T allele (P = 0.006). The study group 
was divided into two subgroups by 60 yr of age, based on a me-
dian age of 56.5 yr; the mean ages of the subgroups were 47.38 ± 
9.4 and 69.83 ± 6.2 yr. In young patients (≤ 60 yr), MTHFR C677T 
mutations were associated with higher VC scores (P = 0.004). In 
young patients, MTHFR C677T mutations were a significant pre-
dictive factor for cerebrovascular accident (CVA) (P = 0.031) 
and PVD (P = 0.006), except ischemic heart disease. The MTH-
FR C677T polymorphism was not associated with plasma Hcy 
levels. 
  A total of 57 (37.5%) patients presented with VC. Extensive VC 
scores (> 3) were observed in 25 (16.4%) of all patients. Table 2 
provides data indicating that the existence of VC was associated 
with a higher frequency of CVD and diabetes (P = 0.001). Pati-
ents with VC had significantly higher systolic blood pressures, 
PWVs, and PPs (P < 0.05). The mean albumin levels were signif-
icantly lower in patients with VC. The frequencies of the MTHFR 
C677T mutation significantly differed between patients with or 
without VC (P = 0.003). However, the plasma Hcy levels did not 
significantly differ between the subgroups. 
  To identify predictors of VC, multiple logistic regression anal-
ysis was performed using the existence of VC as the dependent 
variable and 10 selected variables, including age and gender, as 
the independent variables. Age, diabetes, and MTHFR C677T 
mutations were determined to be independent predictors of 
the existence of VC (Table 3). The adjusted odds ratio (OR) for 
the TT genotype for the risk of extensive VC score (> 3) was 1.66 
(95% confidence interval [CI]; 1.41-19.47, P = 0.013) for all pa-
tients, and 2.41 (95% CI; 1.70-73.29, P = 0.012) for patients young-
er than 60 years of age (data not shown).
  The results of this study suggest that there is a strong relation-
ship between the incidence of MTHFR C677T mutations and VC 
in patients with ESRD on chronic hemodialysis. Compared to 
patients with the CC genotype, patients with CT and TT geno-
types had adjusted ORs for VC of 1.39 and 1.58, respectively (P = 
0.042 and 0.032). In the subgroup analysis, the correlation of the 
MTHFR C677T mutation and VC persisted in young patients (≤ 
60 yr) (Table 1). A similar trend of increased VC scores, although 
not significant, was observed for the older patient group (> 60 
yr). These results suggest that the harmful effect of having a mu-
tant T allele at nucleotide position 677 may be diluted with age, 
which is another strong risk factor for VC. 
  The possible association between a genetic polymorphism 
and the development of VC has been of recent interest to inves-
tigators (8). A better understanding of the pathogenesis contrib-
uting to the increased VC in ESRD patients can provide a better 
perspective on the high cardiovascular mortality, which is par-
tially explained by the traditional risk factors. Several recent re-
ports have suggested that the MTHFR C677T polymorphism (9) 
is associated with the development of CVD in patients with ESRD. 
This is the first study to statistically evaluate the relationship be-
tween the extent of VC and MTHFR C677T polymorphism. 
  The mediator of vascular injury has been presumed to be 
plasma Hcy levels (10), which are increased in patients with mu-
tant T allele (5). However, in this study, plasma Hcy levels were 
not associated with the MTHFR C677T polymorphism and VC. 
There are several possible explanations for these findings. Sev-
eral randomized trials focused on reducing Hcy levels in the 
general population (11) or in patients with ESRD (12) failed to 
improve outcome. Perhaps, lifetime exposure to increased Hcy 
levels cannot be remedied by a few years of partial restoration 
of Hcy levels to normal. Alternatively, high Hcy levels may sim-
ply mark rather than mediate the injury caused by impaired 
MTHFR activity. Recently, the levels of tissue 5-methyl-tetrahy-
drofolate (5-MTHF), rather than plasma or tissue levels of Hcy, 
Table 1. Clinical characteristics according to MTHFR C677T genotypes
Genotypes
No. of  
cases (%)
  Age (yr)
Hcy  
(µmol/L)
VC Score  
(0-8)
PWV  
(cm/s)
CVD (%) IHD (%) CVA (%) PVD (%)
All patients 
   CC
   CT
   TT
   P value
 
44 (28.9)
72 (47.4)
36 (23.7)
 
   61.61 ± 12.4*
  54.24 ± 14.1
  56.17 ± 13.6
0.018
 
16.74 ± 5.5
20.17 ± 8.3
18.91 ± 5.7
0.051
 
0.59 ± 1.5
1.32 ± 2.1
 2.33 ± 2.7
†
0.002
 
1,592.93 ± 394.1
1,503.38 ± 407.0
1,613.79 ± 425.0
0.432
 
38.6
41.7
55.6
0.142
 
38.6
41.7
55.6
0.142
 
31.8
29.2
44.4
0.268
 
2.3
12.5
22.2
0.006
Patients younger than 60 yr old
   CC
   CT
   TT
   P value
 
18 (20.5)
46 (52.3)
24 (27.3)
 
49.72 ± 8.8
  45.89 ± 10.0
48.46 ± 8.3
0.278
 
17.25 ± 5.5
20.24 ± 9.2
18.92 ± 5.1
0.381
 
0.33 ± 1.0
0.91 ± 1.6
 2.29 ± 2.8
†
0.004
 
1,573.10 ± 441.0
1,443.59 ± 404.8
1,595.36 ± 384.5
0.351
 
27.8
28.3
35.2
0.057
 
11.1
17.4
25.0
0.245
 
22.2
19.6
50.0
0.031
 
1.2
6.5
25.0
0.006
Patients older than 60 yr old
   CC
   CT
   TT
   P value
 
26 (40.6)
26 (40.6)
12 (18.8)
 
69.85 ± 6.5
69.00 ± 6.5
71.58 ± 7.3
0.505
 
16.39 ± 5.6
20.05 ± 6.5
18.91 ± 7.5
0.124
 
0.77 ± 1.7
2.04 ± 2.7
2.42 ± 2.5
0.069
 
1,611.35 ± 360.9
1,613.51 ± 398.0
1,654.76 ± 527.6
0.499
 
46.2
65.4
58.3
0.331
 
26.9
30.8
41.7
0.390
 
38.5
46.2
33.3
0.915
 
3.8
23.1
16.7
0.152
*P < 0.05 vs CT and TT genotype by one-way ANOVA with LSD post hoc comparison; 
†P < 0.05 vs CC and CT genotype by one-way ANOVA with LSD post hoc comparison. 
Results are expressed as means ± SD or number of observations (percentage). CVA, cerebrovascular accidents; CVD, cardiovascular disease including ischemic heart disease, 
cerebrovascular accident, and peripheral vascular disease; Hcy, homocysteine; IHD, ischemic heart disease; MTHFR, 5,10-methylenetetrahydrofolate reductase; PVD, peripheral 
vascular disease; PWV, pulse wave velocity; VC Score, vascular calcification score.Lee S-Y, et al.  •  The MTHFR Gene and Vascular Calcifications
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Table 2. Clinical characteristics according to the existence of vascular calcification
Characteristics All patients
According to vascular calcification
Patients without VC Patients with VC P
No. 152 95 57
Male (%) 54.6 56.8 50.9 0.476
Age (yr)    56.83 ± 13.8    56.13 ± 14.0    60.40 ± 12.3 0.852
Duration of hemodialysis (months)    44.74 ± 49.6    43.46 ± 50.3      51.16 ± 46.16 0.480
High flux dialyzer (%) 37.1 35.8 39.3 0.669
Body mass index (kg/m
2)  22.53 ± 3.5  22.64 ± 3.5 21.98 ± 3.4 0.424
Current smoker (%) 10.1 12.0 6.8 0.968
History of cardiovascular disease (%) 44.1 34.7 63.6 0.001
Hypertension (%) 92.1 89.5 96.5 0.112
Diabetes mellitus (%) 53.3 40.0 75.4 < 0.001
Systolic blood pressure (mmHg)  142.28 ± 23.9    140.35 ± 24.20  151.86 ± 20.2 0.044
Diastolic blood pressure (mmHg)    80.20 ± 13.2      80.6 ± 13.2    78.14 ± 13.5 0.437
Pulse pressure (mmHg)    62.22 ± 17.2    59.73 ± 16.8    74.00 ± 14.1 < 0.001
Carotid to femoral PWV (cm/s) 1,554.47 ± 408.1 1,500.89 ± 380.4 1,811.11 ± 448.4 0.002
MTHFR C677T genotype, No. (%)
   CC
   CT
   TT
 
44 (28.9)
72 (47.4)
36 (23.7)
 
36 (37.9)
41 (43.2)
18 (18.9)
 
  8 (14.0)
31 (54.4)
18 (31.6)
0.003
Hemoglobin (g/dL)  10.06 ± 1.4  10.12 ± 1.0    9.76 ± 2.4 0.255
Reticulocyte (%)    0.87 ± 0.5    0.85 ± 0.5    0.95 ± 0.6 0.408
Serum calcium (mg/dL)    9.00 ± 0.9    9.01 ± 0.8    8.92 ± 1.0 0.665
Serum phosphorus (mg/dL)    4.76 ± 1.5    4.76 ± 1.6    4.75 ± 1.3 0.967
Calcium X phosphorus product (mg
2/dL
2)    42.83 ± 14.7    42.93 ± 15.8    42.36 ± 12.2 0.861
Intact parathyroid hormone (pg/mL)    174.97 ± 207.6    188.22 ± 216.0    111.35 ± 148.8 0.092
Serum creatinine (mg/dL)    9.79 ± 3.7  10.03 ± 3.8    8.62 ± 2.9 0.089
Serum albumin (pg/mL)    3.74 ± 0.4    3.77 ± 0.4    3.56 ± 0.4 0.042
Total cholesterol (mg/dL)  134.63 ± 37.8  136.13 ± 38.1  126.52 ± 35.5 0.264
LDL cholesterol (mg/dL)    68.03 ± 33.9    69.69 ± 35.3    59.09 ± 23.4 0.169
HDL cholesterol (mg/dL)    38.55 ± 13.9    37.78 ± 13.1    42.55 ± 15.8 0.118
Triglyceride (mg/dL)    113.74 ± 101.1    119.05 ± 107.3    84.87 ± 49.0 0.137
C-reactive protein (mg/dL)    0.43 ± 0.8    0.38 ± 0.8    0.71 ± 1.0 0.138
KT/V    1.43 ± 0.4    1.43 ± 0.6    1.42 ± 0.7 0.862
Homocysteine (µM/L)    18.9 ± 7.1  18.72 ± 7.3  19.99 ± 6.0 0.454
Folate (ng/mL)    46.73 ± 35.6    46.63 ± 34.6    47.30 ± 41.7 0.937
Medications
   ACE inhibitor/ARBs (%)
   B-blocker (%)
   Calcium channel blocker (%)
   Multi-vitamin supplement* (%)
   Statin
† (%)
 
79.8
38.8
65.1
86.0
49.2
 
76.8
37.8
62.2
85.4
46.9
 
85.1
40.4
70.2
87.2
53.2
 
0.261
0.770
0.360
0.769
0.495
Statistically significant values P < 0.05 in bold. *Multi-vitamin supplement contained 10 mg pyridoxine HCl, 1.5 mg thiamine nitrate, 6 µg cyanocobalamine, 1.7 mg riboflavin, 
60 mg ascorbic acid, 1,000 µg folic acid, 300 µg biotin, 20 mg nicotinamide, and ca. 10 mg pantothenic acid; 
†Cholesterol-lowering HMG-CoA reductase inhibitor. Results are 
expressed as means ± SD or number of observations (percentage). ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; MTHFR, 5,10-methylenetetrahydrofolate reductase; PWV, pulse wave velocity; VC, vascular calcification.
have been suggested to play a role in regulating endothelial func-
tion (13). 
  VC was present in 37.5% of the study participants, which is in-
consistent with the rate of 74.8% reported in a study evaluating 
chronic hemodialysis patients using the same VC scoring meth-
od (7, 14). In this study, mean patient age was 56.83 ± 13.8 yr, 
which is lower than the mean patient age reported in the previ-
ous study (14). Unfortunately, there are limited data available 
on VC in Asian patients assessed using a simple radiogdraphy 
calcification score. 
  There was no significant relationship between MTHFR C677T 
polymorphism and CVD in this study. In the ESRD population, 
evidence for an association of the MTHFR C677T mutation with 
CVD is also inconsistent (9). Since ESRD patients carry a heavy 
cardiovascular disease burden, these conflicting results may re-
flect confounding by various risk factors. Thus, in our study, the 
mean age of the patients with the CC genotype was greater than 
those of the patients with CT or TT. In addition, methodological 
limitations constrain the interpretation of the findings from our 
small-sized cross-sectional study. The prevalence of PVD in-
creased with the incidence of MTHFR C677T mutation for all 
patients, and the CVA also significantly increased for the young Lee S-Y, et al.  •  The MTHFR Gene and Vascular Calcifications
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Table 3. Factors associated with vascular calcification in logistic regression analysis 
Variables
Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Age (yr)  0.029 (1.00-1.05) 0.026 0.073 (1.07-1.02) 0.004
Sex (female/male) -0.240 (0.40-1.52) 0.475 - -
Diabetes mellitus (present/absent)  1.528 (2.22-9.55) 0.000   2.520 (3.59-43.06) 0.006
Pulse pressure (mmHg)  0.031 (1.01-1.05) 0.007 - -
Intact parathyroid hormone (pg/mL) -0.002 (0.99-1.00) 0.035 - -
Serum creatinine (mg/dL) -0.040 (0.87-1.04) 0.370 - -
Serum albumin (pg/mL) -0.426 (0.31-1.35) 0.252 - -
Calcium X phosphorus product (mg
2/dL
2)  0.000 (0.97-1.02) 0.981 - -
Homocysteine (µM/L)  0.043 (0.99-1.09) 0.089 - -
MTHFR C677T genotype*
   CT
   TT
 
 1.224 (1.38-8.34)
   1.504 (1.64-12.31)
 
0.007
0.003
-
  1.394 (1.04-15.62)
  1.580 (1.14-20.50)
-
0.042
0.032
Statistically significant values P < 0.05 in bold. *CC, CT, and TT genotypes were assigned the values of 0, 1, and 2, respectively. MTHFR, 5,10-methylenetetrahydrofolate 
reductase; CI, confidence interval; OR, odds ratio.
patients (≤ 60 yr). Further studies using a larger population are 
required to confirm these findings.
  The MTHFR 677TT genotype was not associated with the 
PWV in this study. It is possible that the association of the MTH-
FR genotype with the PWV was attenuated by several therapeu-
tic interventions such as correction of uremia (15), hypertension 
(16), hyperhomocysteinemia (17), or the use of rennin-angio-
tensin-aldosterone system antagonists (18), statins (19) and/or 
beta blockers (20).
  This study has several limitations. It was a small-sized cross-
sectional study. No variability was determined by repeated mea-
sures of the Hcy or PWV parameters. However, individual inves-
tigators, who were blind to the clinical data, independently re-
ported the VC and PWV measurements. Dietary calcium intake 
was not quantified, and the 25-hydroxy vitamin D levels were 
not determined, which would have been useful for assessing 
VC in the ESRD population.
  In conclusion, the present study indicates that the MTHFR 
C677T mutation is an important factor influencing VC in chron-
ic hemodialysis patients. However, further large-scale studies 
are required to fully characterize the relationship between the 
extent of VC and MTHFR C677T mutational status.
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